Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179955 · ClinicalTrials.gov registry record
Intraoperative Costs and Patient Perceptions in Sacrocolpopexy for Prolapse
A clinical trial of Pelvic Organ Prolapse, sponsored by Mayo Clinic.
- Active
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT04179955: Active study of Pelvic Organ Prolapse, sponsored by Mayo Clinic.
NCT04179955 is a study of Pelvic Organ Prolapse that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 80 participants, below the 143-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04179955, a study of Pelvic Organ Prolapse, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Robotic sacrocolpopexy (a procedure for female pelvic organ prolapse) has been demonstrated to have equivalent surgical outcomes to open abdominal sacrocolpopexy and has been previously deemed more cost effective due to the longer hospital course following open procedures. The total cost of these procedures, including all costs of hospitalization as well as costs associated with the 30 days following surgery have previously been evaluated by the investigators. However, previous research is lacking in both the specific cost components that contribute to intraoperative cost of surgery as well as the patient perceived outcomes following these two procedures. This project aims to evaluate the marginal costs of surgery and to survey sacrocolpopexy patients to evaluate their satisfaction with outcomes and surgical scars.
Primary Outcome
Cost of surgery will be ascertained by summing marginal costs of surgery, including operative and anesthesia time, instruments and medications
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2025-12 |
What the registry record for NCT04179955 still lists
NCT04179955 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 143-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Pelvic Organ Prolapse appearing as the primary indexed condition, and to 0 interventions.
NCT04179955 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04179955 about?
NCT04179955 is a clinical study titled "Intraoperative Costs and Patient Perceptions in Sacrocolpopexy for Prolapse". Robotic sacrocolpopexy (a procedure for female pelvic organ prolapse) has been demonstrated to have equivalent surgical outcomes to open abdominal sacrocolpopexy and has been previously deemed more cost effective due to the longer hospital course following open procedures. The total cost of these pr...
What is the current status of trial NCT04179955?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2019-12-10. Estimated completion is 2025-12.
What conditions does trial NCT04179955 study?
This clinical trial studies the following conditions: Pelvic Organ Prolapse.
Who is sponsoring clinical trial NCT04179955?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04179955 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pelvic Organ Prolapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04179955's enrollment target sits among peer trials
80 26th of 40 higher than 15 of 40 other Pelvic Organ Prolapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pelvic Organ Prolapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Centered Surgery - Preoperative Counseling and Patient Satisfaction
RECRUITING
-
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
RECRUITING
-
Pessary Experience Study
RECRUITING
-
SORE Study: Sitz Baths After Urogynecologic Reconstruction
RECRUITING · NA
-
POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment
RECRUITING · NA
-
Sequence of Midurethral Sling Placement During Robotic Sacrocolpopexy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI